摘要
目的分析非小细胞肺癌患者术后病理分期升级的影响因素。方法回顾性分析2022年5月至2023年5月期间新疆医科大学第六附属医院呼吸科收治的非小细胞肺癌患者124例。收集患者一般临床资料,按照术后是否发生病理分期升级,分为非升级组(n=72)和升级组(n=52)。采用多元线性回归方法,分析影响术后病理分期升级的危险因素。结果单因素分析显示,升级组和非升级组年龄、发现方式、肿瘤直径、术后辅助化疗和术后危险因素评分比较(P<0.05)。多因素分析显示,年龄≥60岁、未术后辅助化疗和术后危险因素评分≥2分是非小细胞肺癌患者术后病理分期升级的危险因素(P<0.05)。非升级组6个月、12个月存活率均高于升级组(P<0.05)。结论非小细胞患者术后病理升级的影响因素多,老年患者、未术后辅助化疗和术后危险因素评分≥2分的患者术后发生病理升级的风险较高,需引起临床高度重视,并及早采取相应的干预措施。
Objective:To analyze the influencing factors of postoperative pathological staging and upgrading in patients with non-small cell lung cancer Methods:From May 2022 to May 2023,124 cases of non-small cell lung cancer were analyzed retrospectively.The general clinical data of patients were collected,and they were divided into non-escalation group(n=72)and escalation group(n=52)according to whether pathological staging occurred after operation.Multiple linear regression method was used to analyze the risk factors affecting the postoperative pathological staging and upgrading.Results:Univariate analysis showed that the age、the way of finding、the diameter of tumor、postoperative adjuvant chemotherapy and postoperative risk factors were compared between the upgraded group and the non-upgraded group(P<0.05).Multivariate analysis showed that age≥60 years、no postoperative adjuvant chemotherapy and postoperative risk factor score≥2 were the risk factors for postoperative pathological staging and upgrading of patients with non-small cell lung cancer(P<0.05).The 6-month and 12-month survival rates of the non-upgraded group were higher than those of the upgraded group(P<0.05).Conclusion:There are many factors influencing postoperative pathological escalation in patients with non-small cell disease.Elderly patients,patients without postoperative adjuvant chemotherapy and patients with postoperative risk factors score≥2 are at higher risk of postoperative pathological escalation,which needs to be paid great attention to in clinic and corresponding intervention measures should be taken as soon as possible.
作者
米丽班古丽·西克然木
Milibanguli Xikeranmu(Department of Pathology,The Sixth Affiliated Hospital of Xinjiang Medical University,Wulumuqi Xinjiang 830092,China)
出处
《生命科学仪器》
2024年第6期73-75,共3页
Life Science Instruments
关键词
非小细胞肺癌
术后辅助化疗
病理分期升级
Non-small cell lung cancer
Postoperative adjuvant chemotherapy
Pathological staging and upgrading
